Sifte Radio

Tag: Medical News

  • WHO Chief Warns Ebola Outbreak Is Outpacing Response as Aid Workers Strike Over Pay

    WHO Chief Warns Ebola Outbreak Is Outpacing Response as Aid Workers Strike Over Pay

    The Director-General of the World Health Organization has warned that the ongoing Ebola virus disease outbreak in the Democratic Republic of the Congo is spreading faster than response efforts, as a strike by aid workers over unpaid salaries threatens to further weaken containment operations.

    The WHO chief said the outbreak has reached a critical stage, with the growing number of infections placing enormous pressure on healthcare systems already struggling with limited resources. He stressed that the response requires urgent financial support, stronger international cooperation, and uninterrupted field operations to prevent the virus from spreading further.

    Compounding the crisis, dozens of frontline aid workers have reportedly suspended their duties, demanding payment of overdue wages and improved working conditions. The strike has disrupted key public health activities, including contact tracing, community education, vaccination campaigns, and patient monitoring.

    Health officials warn that interruptions to these essential services could significantly hamper efforts to contain the outbreak, increasing the risk of additional infections and deaths in affected communities.

    The Democratic Republic of the Congo has experienced multiple Ebola outbreaks over the years, with health authorities relying heavily on international support to combat the deadly virus. The current outbreak has once again highlighted the challenges of responding to infectious diseases in regions facing insecurity, limited healthcare infrastructure, and logistical difficulties.

    The WHO has called on governments, humanitarian organizations, and international donors to provide additional funding to ensure healthcare workers receive the resources and compensation needed to continue their life-saving work.

    Medical experts emphasize that rapid case identification, isolation, vaccination, and community engagement remain the most effective strategies for controlling Ebola outbreaks. They also warn that delays caused by funding shortages or labor disputes could undermine months of progress.

    As authorities work to resolve the strike and strengthen the public health response, international health agencies continue monitoring the situation closely to prevent the outbreak from expanding beyond affected areas.

    Swifteradio.com

  • Canada Approves First Generic Semaglutide Injection for Weight Loss

    Canada Approves First Generic Semaglutide Injection for Weight Loss

    Canada has approved its first generic semaglutide injection for weight loss, marking a significant milestone in expanding access to obesity treatment and potentially lowering costs for patients seeking prescription weight management therapies.

    Health regulators authorized the generic version of semaglutide after determining that it meets the country’s standards for safety, quality, and effectiveness. The approval is expected to introduce greater competition into the market, offering Canadians a more affordable alternative to brand-name medications.

    Semaglutide, a medication that mimics the naturally occurring hormone GLP-1, helps regulate appetite, slows stomach emptying, and promotes feelings of fullness, making it an effective treatment for chronic weight management when used alongside a healthy diet and regular physical activity.

    The drug has gained widespread attention globally for its ability to help individuals with obesity or overweight-related health conditions achieve significant weight loss under medical supervision.

    Healthcare experts say the arrival of a generic version could improve accessibility, particularly for patients who have struggled with the high cost of brand-name semaglutide products.

    Obesity remains a growing public health concern in Canada, contributing to increased risks of conditions such as type 2 diabetes, heart disease, high blood pressure, and certain forms of cancer.

    Medical professionals note that while semaglutide has demonstrated strong clinical results, it is not intended as a standalone solution. Patients are advised to use the medication as part of a comprehensive treatment plan that includes lifestyle modifications and ongoing medical care.

    The approval is also expected to increase competition within the pharmaceutical market, which may encourage lower prices and improved availability for eligible patients.

    Pharmacists and healthcare providers will continue to evaluate individual patient needs before prescribing the medication, ensuring it is used appropriately and safely.

    Industry analysts believe the introduction of a generic alternative could influence healthcare spending while expanding treatment options for Canadians living with obesity.

    The decision reflects Canada’s continued efforts to improve access to innovative and cost-effective medicines while supporting better long-term health outcomes.

    Patients interested in semaglutide treatment are encouraged to consult qualified healthcare professionals to determine whether the medication is appropriate for their specific medical conditions and treatment goals.

    As demand for effective weight management therapies continues to grow worldwide, Canada’s approval of the first generic semaglutide injection represents an important step toward making advanced obesity treatments more accessible to a broader population.

    Swifteradio.com

  • Common Blood-Thinning Drug Neutralizes Cobra Venom

    A team of international scientists has discovered that Heparin, a drug commonly used to thin blood, can be repurposed as a cost-effective antidote to cobra venom. This breakthrough has significant implications for treating snakebites, which kill approximately 138,000 people annually and cause severe injuries to over 400,000 more, predominantly in low- and middle-income countries in Africa, South, and Southeast Asia.

    Cobras, particularly in parts of Africa and India, are responsible for many of these bites. The venom of spitting cobras can cause rapid tissue destruction around the bite area, leading to necrosis. Heparin has been found to neutralize the necrosis-causing toxins in some spitting cobras’ venom. Although not effective against all snake venoms, Heparin offers a cheaper and more flexible alternative to existing antivenoms, which often target only a single snake species and do not prevent necrosis.

    After successful tests on mice, human trials are the next step for this potential treatment.

    Global Fight Against Snakebite

    Professor Greg Neely of the University of Sydney, a senior study author, highlighted the potential impact of this discovery: “Our discovery could drastically reduce the terrible injuries from necrosis caused by cobra bites – and it might also slow the venom, which could improve survival rates.” Neely explained that venoms and toxins interact with human cells in limited ways, suggesting the possibility of developing universal antidotes for various species.

    PhD student Tian Du, the lead author of the study, emphasized the practicality of Heparin: “Heparin is inexpensive, ubiquitous, and a World Health Organization-listed essential medicine. After successful human trials, it could be rolled out relatively quickly to become a cheap, safe, and effective drug for treating cobra bites.”

    Addressing Neglected Tropical Diseases

    Professor Nicholas Casewell, head of the Liverpool School of Tropical Medicine Centre for Snakebite Research and Interventions, noted the broader implications: “Snakebites remain the deadliest of the neglected tropical diseases, with its burden landing overwhelmingly on rural communities in low- and middle-income countries. Our findings are exciting because current antivenoms are largely ineffective against severe local envenoming, which involves painful progressive swelling, blistering, and/or tissue necrosis around the bite site. This can lead to loss of limb function, amputation, and lifelong disability.”

    News Summary: Scientists have found that Heparin, a common blood-thinning drug, can be an effective antidote to cobra venom, particularly in preventing tissue necrosis. This discovery offers hope for a cheaper, more accessible treatment for snakebite victims, primarily in poorer rural areas. Human trials are the next step in validating Heparin’s effectiveness against cobra venom.

    Source: BBC News